The Peggy Lillis Foundation, in coalition with 8 other organizations, recently penned an open letter to the US Food and Drug Administration (FDA) urging the agency’s increased involvement in the development of necessary recurrent C. diff infection treatments and preventatives. “We’ve seen what they could do during COVID-19. If they want to prioritize developing drugs for particular things, then they can put that out there, grease the wheels, so to speak.” Click here to see the full interview and read the full article from HCPLive.